Treatment of prostatic carcinoma by gonadotropin inhibition with danazol. A preliminary report.
The effect of an oral gonadotropin agent--Danazol--on 5 patients with prostatic carcinoma was investigated. A phase 2 pilot study, using a combination of repeated clinical findings, hormone analyses and cytological examinations, allowed some assessment of results after 16 weeks. There was a marked fall in gonadotropin and testosterone serum levels in all patients. Despite a minor rate of cancer remission, results of clinical and cytological examinations were encouraging enough to stimulate further investigations.
D003613:Danazol / Q000009:adverse effects / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D011245:Pregnadienes / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D011245:Pregnadienes; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003613:Danazol